Subscribe

What are you looking for?

Main Menu

明報新聞網

康方生物肺癌藥成為首個入選ASCO全體大會的中國臨牀研究

Future Wealths
Future Wealths
1 6 月, 2026
One Min Read
2 Views
0 Comments
康方生物(9926)公布，其研發的一款肺癌藥物在中國開展的一項後期臨床試驗中，將患者生存期延長了約4個月。彭博報道，富瑞表示，康方生物創造歷史，其數據成為首個入選美國臨牀腫瘤學會(ASCO)全體大會的中國臨牀研究。

原文: https://finance.mingpao.com/fin/instantf/20260601/1780280900522/%E5%BA%B7%E6%96%B9%E7%94%9F%E7%89%A9%E8%82%BA%E7%99%8C%E8%97%A5%E6%88%90%E7%82%BA%E9%A6%96%E5%80%8B%E5%85%A5%E9%81%B8asco%E5%85%A8%E9%AB%94%E5%A4%A7%E6%9C%83%E7%9A%84%E4%B8%AD%E5%9C%8B%E8%87%A8%E7%89%80%E7%A0%94%E7%A9%B6%22%20target=%22blank

Last Update: 1 6 月, 2026

Please share this article if you like it!

Link Copied!
Future Wealths
Written By

Future Wealths

Other Articles

Related Posts

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept